Taccetti G, Procopio E, Marianelli L, Campana S
Cystic Fibrosis Centre, Meyer Hospital, University of Florence, Italy.
Eur J Epidemiol. 2000;16(9):837-42. doi: 10.1023/a:1007670717619.
The prevalence of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) patients is difficult to determine because the data in the literature are not homogeneous or comparable. ABPA and CF have similar clinical symptoms which make diagnosis difficult and underestimate the real dimensions of the problem. We conducted an epidemiological study on 3089 Italian CF patients to determine the prevalence of ABPA in Italy and verify the percentage of positive tests in the employed diagnostic criteria. Our results indicate that the prevalence of ABPA in Italian CF patients is 6.18%, mainly in adolescents and young adults. ABPA is diagnosed using clinical symptoms (presence of episodic bronchial obstructions or typical radiographic features) and on the basis of other criteria which can only be partially fulfilled in paediatric patients. Among the diagnostic tests the most sensitive are the total IgE (84.5%), specific IgE anti-Aspergillus fumigatus (81.6%) and the prick test (68.3%). In the absence of clinical symptoms and gold standard diagnostic tests, serological positivity and/or the skin test are not sufficient evidence to confirm the presence of ABPA.
由于文献中的数据不统一或缺乏可比性,囊性纤维化(CF)患者中变应性支气管肺曲霉病(ABPA)的患病率难以确定。ABPA和CF具有相似的临床症状,这使得诊断困难,并低估了问题的实际规模。我们对3089名意大利CF患者进行了一项流行病学研究,以确定意大利ABPA的患病率,并验证所采用诊断标准中检测呈阳性的百分比。我们的结果表明,意大利CF患者中ABPA的患病率为6.18%,主要发生在青少年和青年成人中。ABPA的诊断依据临床症状(发作性支气管阻塞或典型影像学特征的存在)以及其他标准,但这些标准在儿科患者中只能部分满足。在诊断测试中,最敏感的是总IgE(84.5%)、抗烟曲霉特异性IgE(81.6%)和点刺试验(68.3%)。在没有临床症状和金标准诊断测试的情况下,血清学阳性和/或皮肤试验不足以证实ABPA的存在。